

**King, Valerie A.**

---

**From:** Michael Szwanek (402)437-4880 [Michael.Szwanek@mdsps.com]  
**Sent:** Tuesday, July 01, 2003 7:19 PM  
**To:** maria.gogova@pmusa.com; barbara.k.zedler@pmusa.com; Hans-Juerger.Roethig@pmusa.com; valerie.a.king@pmusa.com; paul.mendes@pmusa.com; qiwei.liang@pmusa.com  
**Cc:** Nancy Wang; Kimberly Prchal; Paul Johnson; Angela Stiens; michael.szwanek@mdsps.com  
**Subject:** Marlboro Long term -MARL/02/03  
**Sensitivity:** Confidential



AA05796\_D1\_01JU AA05796\_01JUL03  
L03\_Philip Morr... ATTACHMENTS\_Ph.

All,

RE: MARL/02/03

Attached is the first draft protocol and selected attachments dated July 1, 2003 for the long-term Marlboro study. This study is scheduled for the July 29, 2003 IRB. All documents will need to final and ready for IRB submission by noon Wednesday, July 23, 2003.

The draft ICF will be completed later this week. We will forward it to you upon completion.

FYI - Short term Marlboro study (MARL/01/03) received IRB approval today (July 1, 2003)

Thanks,

Michael F. Szwanek, Pharm D., MBA  
Section Head, Protocol Development and ICFs  
MDS Pharma Services - Lincoln, NE  
michael.szwanek@mdsps.com  
(402) 437-4880